Clinical Trials Logo

Clinical Trial Summary

The investigators would like to learn more about the metabolic consequences of pseudohypoparathyroidism type 1a in children, adolescents and adults with this condition. People with pseudohypoparathyroidism 1a are at risk for development of obesity. To better understand the cause of overweight or obesity, investigators are measuring body composition and resting energy expenditure (REE), which is the amount of calories burned while completely at rest. The investigators also want to determine the amount of body fat.


Clinical Trial Description

Pseudohypoparathyroidism 1a (PHP1a) is a disorder that is associated with many endocrine problems. People with PHP1a are at risk for the development of obesity. The objective of the study will help determine if obesity is related to abnormalities energy expenditure, meaning that people with PHP1a may not burn as many calories while at rest as those without the disorder.

In order to further evaluate obesity in PHP1a, investigators are planning to measure resting energy expenditure (REE), which is the amount of calories burned while completely at rest. Investigators will also evaluate body composition by looking at measures of growth and development and determining the amount of body fat using dual energy x-ray absorptiometry (DXA) as well as blood and urine biologic markers of obesity. The investigators plan to evaluate people with PHP1a at all weights. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01398774
Study type Observational
Source Children's Hospital of Philadelphia
Contact
Status Terminated
Phase
Start date June 2011
Completion date November 20, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT03029429 - Theophylline Treatment for Pseudohypoparathyroidism Phase 2
Enrolling by invitation NCT04240821 - Theophylline for Treatment of Pseudohypoparathyroidism Phase 2
Completed NCT02463409 - Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy) Phase 2
Terminated NCT03761290 - Glucose Homeostasis in Pseudohypoparathyroidism
Recruiting NCT04551170 - Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old Phase 2
Recruiting NCT00209235 - Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments N/A
Completed NCT02411461 - Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism